AKUMS DRUGS & PHARMACEUTICALS Q2 FY27 CONCALL: TARGETS API BREAKEVEN OVER 3–4 QUARTERS, 8–10% DOMESTIC BRANDED GROWTH; $25 MN ZAMBIA CONTRACT REVENUE EXPECTED IN Q1 FY28, BADDI PLANT TO BE FULLY OPERATIONAL BY Q1 FY28